European ADULT IMMUNISATION HUB

Tag: cost effectiveness

To better understand the fiscal consequences of adult vaccination, a case study was conducted to evaluate comprehensive adult vaccination for those over the age of 50 years in the Netherlands.

Read more

A systematic review of the relevant literature in English on the cost-effectiveness of immunisation for adults aged 50 years or over in all EU Member States was performed for the SAATI report (see below). Cost-effectiveness studies were found for 13 EU Member States (the UK, Germany, the Netherlands, Sweden, Belgium, France, Italy, Spain, Poland, Denmark, Finland, Slovakia and Czech Republic) and for 4 of the seven key vaccine preventable diseases examined in this report: herpes zoster, seasonal influenza, IPD and pneumococcal pneumonia.

Read more